Motor Neurons In Spinal Muscular Atrophy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinal Muscular Atrophy (SMA) is a devastating autosomal recessive neuromuscular disorder characterized by progressive degeneration of spinal motor neurons, leading to severe muscle weakness, atrophy, and often premature death. SMA is caused by deficiency in the Survival Motor Neuron (SMN) protein, which is essential for the survival and function of motor neurons throughout the lifespan. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Motor Neurons | [4]
| Location | Spinal cord anterior horn, brainstem motor nuclei | [5]
| Cell Type | Lower motor neurons (alpha motor neurons) | [6]
| Gene | SMN1 (survival motor neuron 1) | [7]
| Inheritance | Autosomal recessive | [8]
| Incidence | 1 in 6,000-10,000 live births |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000100 | motor neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000100 | motor neuron | Medium |
| Cell Ontology | CL:4042028 | immature neuron | Medium |
The SMN protein is encoded by the SMN1 gene on chromosome 5q13 and is a key component of the SMN complex, which is essential for:
| Mechanism | Description |
|---|---|
| Apoptosis | Caspase-dependent motor neuron death |
| Mitochondrial dysfunction | Energy deficit, ROS accumulation |
| Oxidative stress | Increased reactive oxygen species |
| ER stress | Unfolded protein response activation |
| Neuroinflammation | Glial cell activation |
SMA is classified into types based on age of onset and maximum motor function:
| Type | Onset | Motor Function | Life Expectancy |
|---|---|---|---|
| Type 0 | Prenatal | Severe, fatal | Infancy |
| Type 1 | <6 months | Never sit | <2 years |
| Type 2 | 6-18 months | Sit, never walk | 20-40 years |
| Type 3 | >18 months | Walk | Adult normal |
| Type 4 | Adult | Normal | Normal |
| Model | Features |
|---|---|
| SMNΔ7 mice | Severe SMA phenotype, widely used |
| SMN knockdown zebrafish | Motor axon defects |
| SMN-deficient Drosophila | Motor dysfunction |
| iPSC-derived motor neurons | Patient-specific disease modeling |
The study of Motor Neurons In Spinal Muscular Atrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. 2017. ↩︎
Chaytow H, Huang YT, Gillingwater TH, Faller KM. The role of SMN in RNA metabolism and motor neuron disease. 2018. ↩︎
Martinez TL, Kong L, Wang X, et al. Survival motor neuron protein regulates axonal localization of β-actin mRNA in motor neurons. 2018. ↩︎
Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. 2015. ↩︎
Howell MD, Ottesen SB, Singh AN, et al. Gender influences survival of motor neurons in SMA. 2020. ↩︎
Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of SMN cause motor neuron degeneration? Nat Rev Neurosci. 2009. ↩︎
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. 2017. ↩︎
Mendell JR, Al-Zaidy S, Shell R, et al. Gene Therapy for Spinal Muscular Atrophy. 2017. ↩︎